MedTrace Logo

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-02-24

No results posted yet for this study

Summary

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

Conditions

Interventions

DRUG

129Xe Hyperpolarized

Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).

Sponsors & Collaborators

Principal Investigators

  • Sudarshan Rajagopal, MD, PhD · Duke University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-27
Primary Completion
2029-02-04
Completion
2030-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06351345 on ClinicalTrials.gov